Effect of Folic acid on Serum Homocysteine and Morbidity in Patients with Chronic Coronary Artery Disease
Author(s):
Abstract:
In addition to traditional cardiovascular risk factors, high levels of plasma homocysteine has been documented recently as independent risk factors for atherosclerosis. The probable mechanism is through endothelial dysfunction. Roughly 10% of the population with coronary artery disease (CAD) may have hyper-homocysteinemia. Since folic acid is a potential factor in lowering plasma homocysteine and dietary intake of folic acid is not sufficient, it needs to be prescribed to CAD patients as a supplement. The purpose of this study is to assess the effect of folic acid on plasma homocysteine levels and on morbidity in stable CAD patients.
In this prospective interventional study, we recruited 52 stable CAD patients; the plasma levels of homocysteine, folic acid and vitamin B12 were measured. The morbidity-related indices (the number of sublingual TNGs per week, typical anginal chest pain per week, the number of cardiovascular-related hospitalizations in the previous 3 months, functional class and ECG changes) were determined. All patients received 2 mg oral folic acid daily for 3 months. At the end of the study, the level of homocysteine and morbidity were determined. Effect of Folic Acid on Homocysteine and Morbidity in CAD F. Jalali MD, et al.
Folic acid supplementation for 3 months was associated with a decrease in homocysteine level by 44% (P=0.000). We did not observe a significant change in levels of serum folic acid. There were significant declines in all morbidity indices including TNG consumption, frequency of chest pain, functional class and hospitalizations (P=0.001).
The findings indicate that 2 mg folic acid orally daily for 3 months is associated with a decrease in homocysteine level and morbidity in CAD patients
In this prospective interventional study, we recruited 52 stable CAD patients; the plasma levels of homocysteine, folic acid and vitamin B12 were measured. The morbidity-related indices (the number of sublingual TNGs per week, typical anginal chest pain per week, the number of cardiovascular-related hospitalizations in the previous 3 months, functional class and ECG changes) were determined. All patients received 2 mg oral folic acid daily for 3 months. At the end of the study, the level of homocysteine and morbidity were determined. Effect of Folic Acid on Homocysteine and Morbidity in CAD F. Jalali MD, et al.
Folic acid supplementation for 3 months was associated with a decrease in homocysteine level by 44% (P=0.000). We did not observe a significant change in levels of serum folic acid. There were significant declines in all morbidity indices including TNG consumption, frequency of chest pain, functional class and hospitalizations (P=0.001).
The findings indicate that 2 mg folic acid orally daily for 3 months is associated with a decrease in homocysteine level and morbidity in CAD patients
Keywords:
Language:
English
Published:
Iranian Heart Journal, Volume:8 Issue: 2, Summer 2007
Page:
44
https://magiran.com/p690484
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!